Clinical trials: Psilocybin
Anorexia Nervosa
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study
- Trial name
- NCT05481736
- Testing
- Psilocybin
- Where
- 5 sites in United States, Ireland and 1 more
- Volunteers
- 32 people
- Sponsor
- COMPASS Pathways
Demoralization, Safety
Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer
Demoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness.
- Trial name
- NCT06818994
- Testing
- Psilocybin-assisted Psychotherapy
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Gustavo Vazquez
Treatment Resistant Depression
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.
- Trial name
- PSIHOS-D (NCT06378229)
- Testing
- Psilocybin
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Opioid Dependence, Chronic Pain
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication
This is an open-label pilot trial to assess the safety and feasibility of a novel 8-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients…
- Trial name
- NCT05585229
- Testing
- Psilocybin-assisted Psychotherapy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of British Columbia
Psychogenic Nonepileptic Seizures, Psilocybin
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Psychogenic non-epileptic seizures (PNES) are functional paroxysmal motor disorders that may be clinically suggestive of epilepsy but are not associated with the electroencephysiological and electroencephalographic changes of…
- Trial name
- CRIPSY (NCT06647056)
- Testing
- Psilocybin, MRI
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Healthy
Comparative Acute Effects of LSD, Psilocybin and Mescaline
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor.
- Trial name
- LPM (NCT04227756)
- Testing
- LSD, Psilocybin, Mescaline
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy, Psychedelic Experiences
Consciousness, Psilocybin, and Well-Being
This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
- Conditions
- Healthy, Psychedelic Experiences, Sleep
- Trial name
- CoPE Pilot (NCT05592379)
- Testing
- Psilocybin, Clonidine, Saline
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Psilocybin, Neuropathy
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study…
- Trial name
- NCT07227909
- Testing
- Psilocybin (drug), Standard of Care (SOC)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Obsessive-Compulsive Disorder
Effects of Repeated Psilocybin Dosing in OCD
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess…
- Trial name
- NCT05370911
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Chronic Low Back Pain (CLBP), Physical Therapy
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical…
- Conditions
- Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
- Trial name
- NCT07306364
- Testing
- Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yale University
Functional Neurological Disorder
Psilocybin in Functional Neurological Disorder
The goal of this study is to learn about the brain network response in people who have functional neurological disorder who are administered with a single dose of the psychedelic psilocybin with therapeutic support.
- Trial name
- PsiFUND (NCT05723276)
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Major Depressive Disorder
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder.
- Trial name
- NCT03554174
- Testing
- Low Dose Psilocybin, Medium Dose Psilocybin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Healthy
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of…
- Trial name
- NCT05301608
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Opioid Use Disorder
Psilocybin for Opioid Use Disorder (OUD)
This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who…
- Trial name
- NCT06796062
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 480 people
- Sponsor
- NYU Langone Health
Psychedelic Experiences, Neuroimaging
Neural and Physiological Correlates of Psychedelic Sub-states
The main purpose of this study is to gain a better understanding of the distinct mental states and physical reactions that can arise during a psychedelic experience.
- Conditions
- Psychedelic Experiences, Neuroimaging, Healthy Volunteers
- Trial name
- i2 (NCT05698511)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Robin Carhart-Harris, PhD, MA
Depression
Psilocybin-Assisted Therapy as a Treatment for Depression
Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common.
- Trial name
- NCT07582120
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Depression - Major Depressive Disorder, Psilocybin
Group PACBT for Depression
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the…
- Conditions
- Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
- Trial name
- NCT07566104
- Testing
- Psilocybin (drug), Group Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Cancer
Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
This pilot project is an open-label trial that will offer psilocybin in a group format to assess the feasibility of offering psilocybin therapy in a group setting with a decreased therapist to subject ratio.
- Trial name
- HOPE (NCT04522804)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah